论文部分内容阅读
2013年6月13日,美国最高法院的九位大法官在Associationfor Molecular Pathology诉Myriad Genetics案中一致裁定,根据美国专利法第101条(35U.S.C.§101),从人体分离的基因(天然存在的DNA片段)不是专利保护客体,理由是所述基因涉及“天然产物”。本案针对Myriad公司拥有的几项涉及BRCA1和BRCA2基因(在乳腺癌和卵巢癌中重要的基因)的专利,涉及权利要求撰写形式为“编码BRCA1多肽的分离的DNA”等。在本案中美国最高法院认为:“Myriad公司没有创造任何事物……其发现了重要和有用的基因,但是从基因的周围遗传材料中将基因分离出来并不是
On June 13, 2013, all nine judges of the Supreme Court of the United States of America, in Associationfor Molecular Pathology v. Myriad Genetics, unanimously held that a gene isolated from the human body (naturally present in accordance with section 101 of the U.S. Patent Act (35U.SC §101) DNA fragment) is not a patent protection object, the reason is that the gene involved ”natural product “. My case contains several patents owned by Myriad that deal with the BRCA1 and BRCA2 genes (genes important in breast and ovarian cancer), and claims related to ”isolated DNA encoding a BRCA1 polypeptide“ and the like. In this case, the Supreme Court of the United States held that ”Myriad did not create anything ... it discovered important and useful genes, but separating the genes from the genetic material around the genes was not